Staphylococcal resistance to antimicrobial peptides of mammalian and bacterial origin

Peptides

Volumn 22, Issue 10, 2001, Pages 1651-1659

  Peschel, Andreas ^a   Vincent Collins, L ^b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

ABC transporters; Animal studies; Bacteriocins; Defensins; Host defense peptides; Immunomodulation; Innate immunity; Lantibiotics; Platelet microbicidal proteins; Protegrins; Secondary transporters; Staphylococcus aureus; Teichoic acids; Thrombocidins

Indexed keywords

ABC TRANSPORTER; BACTERIAL DNA; BACTERIOCIN; CATHELICIDIN; CECROPIN; CYTOLYSIN; DEFENSIN; EPICIDIN; EPIDERMIN; EPILANCIN; LANTHIONINE; LANTIBIOTIC; LIPOTEICHOIC ACID; MELITTIN; PEPTIDOGLYCAN; POLYPEPTIDE ANTIBIOTIC AGENT; PROTEGRIN; TEICHOIC ACID; TEICOPLANIN; THROMBOCIDIN DERIVATIVE; UNCLASSIFIED DRUG; VANCOMYCIN; VIRULENCE FACTOR;

ANTIBIOTIC RESISTANCE; ANTIMALARIAL ACTIVITY; BACTERIAL COLONIZATION; BACTERIAL VIRULENCE; DRUG EFFECT; EPITHELIUM; HOST RESISTANCE; IMMUNITY; IMMUNOMODULATION; NONHUMAN; PHAGOCYTE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; REVIEW; SKIN; SPECIES DIFFERENCE; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; STRUCTURE ACTIVITY RELATION; THROMBOCYTE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTI-BACTERIAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; BACTERIA; DRUG RESISTANCE; HUMANS; IMMUNITY, NATURAL; MAMMALS; MOLECULAR SEQUENCE DATA; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

ANIMALIA; BACTERIA (MICROORGANISMS); MAMMALIA; STAPHYLOCOCCI; STAPHYLOCOCCUS AUREUS;

EID: 0034831625     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0196-9781(01)00500-9     Document Type: Review

References (102)

1. Role of T lymphocytes in experimental Staphylococcus aureus arthritis
2. Biosynthesis of the lantibiotic mersacidin: Organization of a type B lantibiotic gene cluster
3. Genetic analysis of epidermin biosynthetic genes and epidermin-negative mutants of Staphylococcus epidermidis
4. Instruments of microbial warfare: Bacteriocin synthesis, toxicity and immunity
5. Transfer of a cathelicidin peptide antibiotic gene restores bacterial killing in a cystic fibrosis xenograft model
6. In vitro resistance to thrombin-induced platelet microbicidal protein among clinical bacteremic isolates of Staphylococcus aureus correlates with an endovascular infectious source
7. In vitro resistance of Staphylococcus aureus to thrombin-induced platelet microbicidal proteins is associated with alterations in cytoplasmic membrane fluidity
8. Antimicrobial peptides as agents of mucosal immunity
9. The biosynthesis of the lantibiotics epidermin, gallidermin, pep5 and epilancin K7
10. Experimental Staphylococcus aureus arthritis in mice
11. Use of the cell wall precursor lipid II by a pore-forming peptide antibiotic
12. Role of lipid-bound peptidoglycan precursors in the formation of pores by nisin, epidermin and other lantibiotics
13. PR-39, a syndecan-inducing antimicrobial peptide, binds, and affects p130(Cas)
14. Animal models of experimental Staphylococcus aureus infection
15. Involvement of bactericidal factors from thrombin-stimulated platelets in clearance of adherent viridans streptococci in experimental infective endocarditis
16. The cell wall components peptidoglycan and lipoteichoic acid from Staphylococcus aureus act in synergy to cause shock and multiple organ failure
17. Intra-articularly localized bacterial DNA containing CpG motifs induces arthritis
18. In vitro resistance to thrombin-induced platelet microbicidal protein is associated with enhanced progression and hematogenous dissemination in experimental Staphylococcus aureus infective endocarditis
19. Phenotypic resistance to thrombin-induced platelet microbicidal protein in vitro is correlated with enhanced virulence in experimental endocarditis due to Staphylococcus aureus
20. Transcriptional regulation of β-defensin gene expression in tracheal epithelial cells
21. Chemical composition and structure of the cell wall teichoic acids of staphylococci
22. Lipoteichoic acid and teichoic acid biosynthesis. Targets of new antibiotics?
23. Physiology of lipoteichoic acids in bacteria
24. Monitoring bioluminescent Staphylococcus aureus infections in living mice using a novel luxABCDE construct
25. Antimicrobial peptides: An emerging concept in cutaneous biology
26. Defensins and host defense
27. Serine protease EpiP from Staphylococcus epidermidis catalyzes the processing of the epidermin precursor peptide
28. Genetic structure of the Enterococcus faecalis plasmid pAD1-encoded cytolytic toxin system and its relationship to lantibiotic determinants
29. Human β-defensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis
30. Peptide antibiotics
31. The role of cationic antimicrobial peptides in innate host defences
32. A peptide antibiotic from human skin
33. Isolation and characterization of Human {beta}-Defensin-3, a novel human inducible peptide antibiotic
34. Isolation, characterization, and heterologous expression of the novel lantibiotic epicidin 280, and analysis of its biosynthetic gene cluster
35. ABC transporters: From microorganisms to man
36. A dual role of GdmH in producer immunity, and secretion of the staphylococcal lantibiotics gallidermin, and epidermin
37. Phylogenetic perspectives in innate immunity
38. Chemoattractant properties of PR-39, a neutrophil antibacterial peptide
39. Genes involved in self-protection against the lantibiotic subtilin produced by Bacillus subtilis ATCC 6633
40. Taxonomy and systematics of staphylococci indigenous to humans
41. Nasal carriage of Staphylococcus aureus: Epidemiology, underlying mechanism, and associated risk
42. Thrombocidins, microbicidal proteins from human blood platelets, are C-terminal deletion products of CXC chemokines
43. Plasmid-mediated resistance to thrombin-induced platelet microbicidal protein in staphylococci: Role of the qacA locus
44. Expression, purification, and characterization of EpiC, an enzyme involved in the biosynthesis of the lantibiotic epidermin, and sequence analysis of Staphylococcus epidermidis epiC mutants
45. Mass spectroscopic analysis of a novel enzymatic reaction
46. Expression of human β-defensin 1 mRNA in human nasal mucosa
47. Multidrug resistance to antiseptics and disinfectants in coagulase-negative staphylococci
48. Antimicrobial peptides in mammalian and insect host defence
49. Chronic granulomatous disease in adults
50. Staphylococcus aureus infections
51. Purification and identification of formyl-methionyl-leucyl-phenylalanine as the major peptide neutrophil chemotactic factor produced by Escherichia coli
52. Peptidoglycan and teichoic acid from Staphylococcus epidermidis stimulate human monocytes to release tumor necrosis factor (TNF) α, interleukin-1 (IL-1)β, and IL-6
53. Nucleotide sequence of the lantibiotic Pep5 biosynthetic gene cluster and functional analysis of PepP and PepC
54. QacA multidrug efflux pump from Staphylococcus aureus: Comparative analysis of resistance to diamidines, biguanidines, and guanylhydrazones
55. Bioenergetics of the staphylococcal multidrug export protein QacA. Identification of distinct binding sites for monovalent and divalent cations
56. Role of neutrophil leukocytes in cutaneous infection caused by Staphylococcus aureus
57. Identification of genes encoding two-component lantibiotic production in Staphylococcus aureus C55 and other phage group II S. aureus strains and demonstration of an association with the exfoliative toxin B gene
58. Staphylococcal carriage and skin and soft tissue infection
59. Producer self-protection against the lantibiotic epidermin by the ABC transporter EpiFEG of Staphylococcus epidermidis Tü3298
60. Molecular analysis of expression of the lantibiotic Pep5 immunity phenotype
61. Multidrug resistance proteins QacA and QacB from Staphylococcus aureus: Membrane topology and identification of residues involved in substrate specificity
62. Resistance to antimicrobial agents other than β-lactams
63. Regulation of epidermin biosynthetic genes by EpiQ
64. Analysis of the Staphylococcus epidermidis genes epiF, E, and G involved in epidermin immunity
65. Inducible production and cellular location of the epidermin biosynthetic enzyme EpiB using an improved staphylococcal expression system
66. Inactivation of the dlt operon in Staphylococcus aureus confers sensitivity to defensins, protegrins and other antimicrobial peptides
67. Secretion of the lantibiotics epidermin and gallidermin: Sequence analysis of the genes gdmT and gdmH, their influence on epidermin production and their regulation by EpiQ
68. The D-alanine residues of Staphylococcus aureus teichoic acids alter the susceptibility to vancomycin, and the activity of autolysins
69. The molecular basis of pathogenicity
70. The ecological role of bacteriocins in bacterial competition
71. Staphylococcus aureus tetrapeptide with high chemotactic potency, and efficacy for human leukocytes
72. Lantibiotics: Biosynthesis, and biological activities of uniquely modified peptides from Gram-positive bacteria
73. Complement depletion aggravates Staphylococcus aureus septicaemia and septic arthritis
74. Inhibition of nitric oxide synthase (NOS) aggravates Staphylococcus aureus septicaemia and septic arthritis
75. Interaction with complement receptor 1 (CD35) leads to amelioration of sepsis-triggered mortality but aggravation of arthritis during Staphylococcus aureus infection
76. The cell envelope
77. Prepeptide sequence of epidermin, a ribosomally synthesized antibiotic with four sulphide-rings
78. Interaction of cationic peptides with lipoteichoic acid and Gram-positive bacteria
79. An α-helical cationic antimicrobial peptide selectively modulates macrophage responses to lipopolysaccharide, and directly alters macrophage gene expression
80. Metabolism of phosphatidylglycerol, sylphosphatidylglycerol, and cardiolipin of Staphylococcus aureus
81. Genes involved in immunity to the lantibiotic nisin produced by Lactococcus lactis 6F3
82. Antibiotic proteins of human neutrophils
83. Protegrin-1: A broad-spectrum, rapidly microbicidal peptide with in vivo activity
84. Effect of thrombocytopenia on the early course of streptococcal endocarditis
85. A cyclic antimicrobial peptide produced in primate leukocytes by the ligation of two truncated α-defensins
86. Studies on prolysostaphin processing and characterization of the lysostaphin immunity factor (Lif) of Staphylococcus simulans biovar staphylolyticus
87. Induction of release of TNF from human monocytes by staphylococci and staphylococcal peptidoglycans
88. Bactericidal activity of mammalian cathelicidin-derived peptides
89. Sequence analysis by NMR spectroscopy of the peptide lantibiotic epilancin K7 from Staphylococcus epidermidis K7
90. Drug efflux proteins in multidrug resistant bacteria
91. Modulation of neutrophil chemokine receptors by Staphylococcus aureus supernate
92. Role of neutrophils in experimental septicemia and septic arthritis induced by Staphylococcus aureus
93. Host defense against infection
94. Interactions between human defensins and lipid bilayers: Evidence for formation of multimeric pores
95. Human neutrophil defensins selectively chemoattract naive T and immature dendritic cells
96. LL-37, the neutrophil granule-, and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells
97. The role of platelets in antimicrobial host defense
98. Platelet microbicidal proteins and neutrophil defensin disrupt the Staphylococcus aureus cytoplasmic membrane by distinct mechanisms of action
99. Partial characterization and staphylocidal activity of thrombin-induced platelet microbicidal protein
100. Mice with the xid B cell defect are less susceptible to developing Staphylococcus aureus-induced arthritis
101. Staphylococcus aureus resistance to human defensins and evasion of neutrophil killing via the novel virulence factor MprF is based on modification of membrane lipids with L-lysine